Significant ecological impact on the progression of fluoroquinolone resistance in Escherichia coli with increased community use of moxifloxacin, levofloxacin and amoxicillin/clavulanic acid

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 3, 2011, Pages 664-669

  Cuevas, Oscar ^a   Oteo, Jesús ^a   Lázaro, Edurne ^b   Aracil, Belén ^a   de Abajo, Francisco ^c   García Cobos, Silvia ^a   Ortega, Adriana ^a   Campos, José ^a,d  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b Ministry of Health   (Spain)

^c HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^d CSIC   (Spain)

Author keywords

Antimicrobial susceptibility; E. coli; Invasive pathogens

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEPHALOSPORIN; EXTENDED SPECTRUM BETA LACTAMASE; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; COMMUNITY MEDICINE; CORRELATION ANALYSIS; DRUG USE; ECOLOGY; ESCHERICHIA COLI; GRAM NEGATIVE SEPSIS; HOSPITAL INFECTION; MICROBIOLOGICAL PARAMETERS; NONHUMAN; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; AZA COMPOUNDS; BACTEREMIA; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FLUOROQUINOLONES; HOSPITALS; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; QUINOLINES; SPAIN; YOUNG ADULT;

EID: 79951521947     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq471     Document Type: Article

References (14)

1. Oteo J, Campos J, Lázaro E et al. Increased amoxicillin-clavulanic acid resistance in Escherichia coli blood isolates, Spain. Emerg Infect Dis 2008; 14: 1259-62.
2. Lark RL, Saint S, Chenoweth C et al. Four-year prospective evaluation of community-acquired bacteremia: epidemiology, microbiology and patient outcome. Diagn Microbiol Infect Dis 2001; 41: 15-22.
3. Oteo J, Lázaro E, de Abajo FJ et al. Antimicrobial-resistant invasive Escherichia coli, Spain. Emerg Infect Dis 2005; 11: 546-53.
4. Ferech M, Coenen S, Malhotra-Kumar S et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe. J Antimicrob Chemother 2006; 58: 423-7.
5. Bergman M, Nyberg ST, Huovinen P et al. Association between antimicrobial consumption and resistance in Escherichia coli. Antimicrob Agents Chemother 2009; 53: 912-7.
6. van de Sande-Bruinsma N, Grundmann H, Verloo D et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 2008; 14: 1722-30.
7. Karroll CC, Weinstein MP. Manual and automated systems for detection and identification of microorganisms. In: Murray PR, ed. Manual of Clinical Microbiology. 9th edn. Washington, DC: ASM Press, 2007; 192-217.
8. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement M100-S20. CLSI, Wayne, PA, USA, 2010.
9. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. Oslo: WHO, 2005.
10. Oteo J, Bautista V, Lara N et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum β-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother 2010; 65: 2459-63.
11. Chenia HY, Pillay B, Pillay D. Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens. J Antimicrob Chemother 2006; 58: 1274-8.
12. Livermore DM, Hope R, Brick G et al. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008; 62 Suppl 2: ii41-54.
13. Sundqvist M, Geli P, Andersson DI et al. Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. J Antimicrob Chemother 2009; 65: 350-60.
14. Gallini A, Degris M, Desplas R et al. Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital. J Antimicrob Chemother 2010; 65: 2650-7.